10 results about "Guluronic acid" patented technology

The present invention relates to tablet, capsule and ampoule formulations for oral and / or injectable use, said formulations comprising beta-D-mannuronic acid or alpha-L-guluronic acid or a mixture of beta-D-mannuronic acid and alpha-L-guluronic acid, their oligomers, or their pharmaceutically acceptable salts, the total amount of [beta]-D-mannuronic acid or [alpha]-L-guluronic acid or mixtures thereof, oligomers thereof, or pharmaceutically acceptable salts thereof is from 10% to 99.999% by weight, based on the total weight of the tablet or capsule formulation, or from 20% to 60% by weight, based on the total weight of the ampoule formulation; the tablet, capsule or ampoule formulation further comprises caffeic acid or a salt thereof, for example in powder form, in an amount preferably from 0.001 wt% to 1 wt%, more preferably from 0.01 wt% to 0.5 wt%, more preferably from 0.05 wt% to 0.3 wt%, based on the total weight of the tablet, capsule or ampoule formulation. Furthermore, the present invention relates to the oral and / or injectable use of tablet, capsule and ampoule formulations, preferably as supplements or medicaments, for use in methods for the treatment of neurodegenerative diseases, inflammatory responses, pain, cancer, aging, diabetes and / or heart diseases, as well as to methods of preparing such formulations.

The present invention relates to a gel or cream formulation for topical use, the formulation comprising beta-D-mannuronic acid or alpha-L-guluronic acid or a mixture of beta-D-mannuronic acid and alpha-L-guluronic acid, their oligomers or their pharmaceutically acceptable salts, where, based on 100 g of the gel or cream formulation, the content of the beta-D-mannuronic acid or alpha-L-guluronic acid or the mixture of beta-D-mannuronic acid and alpha-L-guluronic acid or alpha-L-guluronic acid or alpha-L-guluronic acid or alpha-L-guluronic acid or alpha- the total amount of beta-D-mannuronic acid or alpha-L-guluronic acid or a mixture of beta-D-mannuronic acid and alpha-L-guluronic acid, their oligomers or their pharmaceutically acceptable salts is from 0.5 g to 40 g, said formulation further comprising caffeic acid. Furthermore, the present invention relates to a gel or cream formulation for topical use in a method of treating inflammation and / or any inflammatory response and / or pain, as well as a method of preparing the gel or cream formulation.

The application discloses a novel brown algae polysaccharide SARP for promoting healing of diabetic ulcers and a preparation and application thereof. A novel SARP is obtained through Sephacryl S-300 / HR gel column separation and purification, and the molecular weight of the SARP is about 45.4 kDa, which is composed of mannuronic acid (76.56%), guluronic acid (18.89%) and a small amount of glucuronic acid (4.55%). Compared with alginate separated from other brown algae, the SARP has a higher content of mannuronic acid. The SARP shows a better in-vitro antioxidant capacity, and can obviously reverse the cell damage of HUVECs caused by H2O2 and high sugar in the HUVECs. In addition, the SARP can promote the migration and tubular formation of the HUVECs. In-vivo experiments further show that the SARP can promote the healing of diabetic ulcer in rats, and can reduce the oxidative stress, inflammation level and lipid disorder in the rats. The SARP has a simple purification route, can be prepared in a large amount, and is a very promising novel drug for treating diabetic foot ulcers.

The invention described herein include the conversion of alginate that do not have the required mechanical and chemical properties for their use as alginate raft-forming oral suspension (AROS) for Gastroesophageal reflux disease (GERD) therapy into compliant alginate polysaccharides for AROS. The invention consists of the reaction of an epimerase enzyme with alginate polysaccharides containing a high amount of β-D-mannuronic acid sugars in their backbone to obtain alginate polysaccharide with high α-L-guluronic acid content. The reaction of the AlgE6R enzyme converts mannuronic sugars into guluronic sugars by creating long sequence of guluronic sugars increasing the blockiness of the resulting alginate. The invention combines the enzymatic treatment with a hydrolysis step to obtain alginate solutions that not only forms strong hydrogel but exhibit low viscosity in raft formulation offering the possibility to provide a better swallowability for GERD patients.

A nanoparticle comprising a diblock polymer comprising a first component covalently bound via a linker to a second component; wherein said first component is an oligomer comprising at least 50 mol% L-5 guluronic acid residues or at least 50 mol% galacturonic acid residues and having a degree of polymerisation n where n is at least 3; said second component is a second polymer having no more than 30 mol% L-guluronic acid residues or galacturonic acid residues and having a degree of polymerisation of at least 4;10 wherein said nanoparticle comprises a chelator such as DOTA; wherein said nanoparticle comprises at least one metal ion such as a radionuclide or Gd ions.

The invention discloses a method for realizing multi-dimensional improvement of anthocyanin performance by utilizing homopolyguluronic acid oligosaccharide compounding, and relates to the technical field of food science and engineering. The method for improving the performance of the anthocyanin in multiple dimensions is provided by constructing a composite system of homopolyguluronic acid oligosaccharide and the anthocyanin, a homopolyguluronic acid oligosaccharide solution and an anthocyanin solution are mixed on the basis of unique alpha-1, 4 glucosidic bond folding conformation of the homopolyguluronic acid oligosaccharide, and the homopolyguluronic acid oligosaccharide-anthocyanin composite material is obtained. And stirring to form the homopolyguluronic acid oligosaccharide and anthocyanin compound with a stable space structure. A physical mixing method is adopted, so that the edible safety of the product is ensured while the technological process is simplified. The homopolyguluronic acid oligosaccharide and anthocyanin compound provided by the invention can keep stable under wider environmental conditions, can better protect the anthocyanin, and promotes the antioxidant effect and color improvement effect of the anthocyanin. The method has a good application prospect in the field of food processing.

The present invention relates to a topical gel or cream formulation containing β-D-mannuronic acid, α-L-guluronic acid, a mixture of β-D-mannuronic acid and α-L-guluronic acid, their oligomers, or pharmaceutically acceptable salts, wherein the total amount of β-D-mannuronic acid, α-L-guluronic acid, or the mixture of β-D-mannuronic acid and α-L-guluronic acid, their oligomers, or pharmaceutically acceptable salts is 0.5 g to 40 g per 100 g of the gel or cream formulation, and further containing caffeic acid. The present invention also relates to a topical gel or cream formulation for use in a method for treating inflammation and / or any inflammatory response and / or pain, and to a method for producing the gel or cream formulation.

The invention discloses a method for preparing L-guluronic acid, and belongs to the technical field of bioengineering and enzyme engineering. According to the present invention, galactose oxidase (GOA) is adopted to catalyze gluconic acid (Glucic acid) so as to generate the L-guluronic acid (L-guluronic acid), and the L-guluronic acid (L-guluronic acid) can be used to catalyze the L-guluronic acid (L-guluronic acid), such that the L-guluronic acid (L-guluronic acid) can be obtained; furthermore, according to the invention, the galactose oxidase from fusarium graminearum is subjected to enzyme engineering modification, the galactose oxidase mutant is provided, and the activity of the galactose oxidase mutant for catalyzing oxidation of gluconic acid to generate L-guluronic acid is obviously improved. Compared with the existing production technology, the method for producing the L-guluronic acid by using the enzyme catalysis method provided by the invention has the advantages of simple production process, environmental friendliness, high yield, easiness in large-scale preparation and the like.

The invention relates to the field of development of natural products, in particular to pholiota nameko polysaccharide with an effect of improving ulcerative colitis as well as a preparation method and application of the pholiota nameko polysaccharide. The pholiota nameko polysaccharide PNP-1a comprises the following components in percentage by mole: 11.70% of galactose, 32.34% of glucose, 9.16% of xylose, 33.71% of mannose, 4.05% of galacturonic acid, 1.31% of guluronic acid and 7.73% of glucuronic acid. And the molecular weight range is 62 kDa to 236 kDa. The biological function and application value of the pholiota nameko polysaccharide in preventing and / or improving ulcerative colitis and related diseases are verified, and a scientific basis is provided for developing functional foods or medicines for preventing and / or improving ulcerative colitis based on the pholiota nameko polysaccharide.

The invention provides a mannose-guluronic acid sodium copolymer and a preparation method thereof. The preparation method comprises the following steps: preparing a sodium alginate-sodium chloride solution; performing foaming mixing on the sodium alginate-sodium chloride solution and an acidic calcium chloride solution; removing low-molecular substances in the solution by using a micro-filtration membrane; after the solution is concentrated, carboxyl is reduced through carboxyl reductase; carrying out decalcification treatment on the reaction liquid; carrying out spiral squeezing dehydration on the decalcified material to obtain a solid, and immersing the solid in alcohol with the concentration of 60-80% to adjust the pH value to 6-8; and granulating and crushing to obtain a target product, namely the Manp-GulpA copolymer. The carboxyl reductase with high selectivity is adopted, only carboxyl of uronic acid is reduced into primary hydroxyl by controlling reaction conditions, compared with sodium alginate, the prepared Manp-GulpA copolymer is easier to dissolve in a weakly acidic environment, and the reaction process is safe and environmentally friendly.